Agios Pharmaceuticals, Inc. (AGIO), Wednesday said that the European Commission has adopted a positive decision for the orphan medicinal product designation of mitapivat for sickle cell disease.
In Novemeber 2020, the FDA had granted orphan drug designation to mitapivat for sickle cell disease.
The company expects to announce results from its Phase 3 RISE UP study of mitapivat in sickle cell disease in late 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.